USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PARION SCIENCES, INC.
City: DURHAM
State: NC
Zip+4: 27713-2261
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,577,573.00 5
SBIR Phase II $3,931,986.00 4

Award List:

PHARMACOTHERAPY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Samuel E. Hopkins
Award Amount: $489,999.00
Abstract:
DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disorder characterized by lymphocyte-mediated destruction ofOverall, this application was found to have significant and substantial scientific merit, and is recommended with an exc exocrine glands and… More

DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Samuel E. Hopkins
Award Amount: $364,501.00
Abstract:
DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary clearance and is well tolerated when administered as a single dose by inhalation aerosol in normal… More

DEVELOPMENT OF EPITHELIAL SODIUM CHANNEL BLOCKERS FOR CF

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Judith A. Stgeorge
Award Amount: $983,544.00
Abstract:
DESCRIPTION (provided by applicant): Our preliminary data support the hypothesis that 552-02 is a potent, selective inhibitor of epithelial sodium channels that is effective in enhancing mucociliary clearance and is well tolerated when administered as a single dose by inhalation aerosol in normal… More

PHARMACOTHERAPRY FOR XEROSTOMIA IN SJOGREN'S SYNDROME

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Karl Donn
Award Amount: $379,296.00
Abstract:
DESCRIPTION (provided by applicant): Sjogren's syndrome (SS) is a slowly progressive inflammatory disease characterized by lymphocyte- mediated destruction of exocrine glands and internal organ involvement due to autoantibody production or pre- existing co nnective tissue disorder. Over time,… More

The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Karl H. Donn
Award Amount: $159,264.00
Abstract:
DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial disease, resulting from a common etiology of insufficient t ear film causing ocular surface damage and… More

Hypertonic Saline for Cystic Fibrosis

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Benjamin Yerxa – 919-941-9777
Award Amount: $244,797.00
Abstract:
DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, is caused by dehydration of airway secretions that leads to mucous adhesion, infection and airways… More

The Development Epithelial Sodium Channel Blockers for Chronic Dry Eye

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Karl H. Donn – 919-313-1185
Award Amount: $1,059,726.00
Abstract:
DESCRIPTION (provided by applicant): Dry eye is one of the most frequently diagnosed ocular diseases affecting more than 5 million people in the United States alone. Dry eye is s a multi-factorial disease, resulting from a common etiology of insufficient tear film causing ocular surface damage and… More

Novel Mucolytic Agents

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bill Thelin – 919-313-1199
Award Amount: $319,012.00
Abstract:
DESCRIPTION (provided by applicant): Mucus transport is the fundamental defense of the airways against inhaled particulates/infectious agents. Abnormalities in the mucus transport system characterize a complex of muco-obstructive airway diseases, such as cystic fibrosis (CF) and chronic bronchitis… More

Hypertonic Saline for Cystic Fibrosis

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bill Thelin – 919-313-1199
Award Amount: $1,509,420.00
Abstract:
DESCRIPTION (provided by applicant): Cystic fibrosis (CF) is an autosomal lethal disease characterized that affects ~30,000 individuals in the US. CF lung disease, the major cause of mortality in CF, is caused by dehydration of airway secretions that leads to mucous adhesion, infection and airways… More